Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. US20020077359 - Method of treating benign prostatic hyperplasia and other benign prostate conditions

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

What is claimed is:

1. A method of treatment of benign prostatic hyperplasia comprising the steps of:
(a) orally administering an initial dosage of about 40 mg of 13-cis-retinoic acid daily for an initial treatment period from about ten days to about twenty days, and
(b) thereafter orally administering a sustaining dosage of about 40 mg of 13-cis-retinoic acid about every five to seven days in a sustaining period.
2. The method of claim 1 wherein said sustaining period is about one year.
3. The method of claim 1 wherein said initial treatment period is about fourteen days.
4. The method of claim 1 wherein said 13-cis-retinoic acid is in a form selected from the group consisting of powder, pill, capsule, tablet, and liquid.
5. The method of claim 4 wherein said liquids comprise 13-cis-retinoic acid in a pharmaceutical media selected from the group consisting of water, glycol, oil, alcohol, and syrup.
6. A method of reduction of a level of a prostate specific antigen (PSA) of benign prostate conditions comprising the steps of:
(a) orally administering an initial dosage of about 40 mg of 13-cis-retinoic acid daily for an initial treatment period from about ten days to about twenty days, and
(b) thereafter orally administering a sustaining dosage of about 40 mg of 13-cis-retinoic acid about every five to seven days in a sustaining period.
7. The method of claim 6 wherein said sustaining period is about one year.
8. The method of claim 6 wherein said initial treatment period is about fourteen days.
9. The method of claim 6 wherein said 13-cis-retinoic acid is in a form selected from the group consisting of powder, pill, capsule, tablet, and liquid.
10. The method of claim 9 wherein said liquids comprise 13-cis-retinoic acid in a pharmaceutical media selected from the group consisting of water, glycol, oil, alcohol, and syrup.